The gene expression of a new group of tumour antigens known as cancer/testis (CT) antigens is now well-recognized in some solid tumours. However, their expression in haematological malignancies remained unclear. In this study, we have used reverse transcription polymerase chain reaction and Southern blot analysis to examine the presence of transcripts for the three CT antigens, NY-ESO-1, SSX2 and SCP1 in haematological malignant cells. We found that transcripts for SCP1 could be detected in 10% of myeloma, 5.7% of acute myeloid leukaemia and 23% of chronic myeloid leukaemia. In contrast, NY-ESO-1 and SSX2 were not detected in any of the 107 tumour samples.
Various laboratory studies have indicated that haematological malignancies may be amenable to immune targeting. In Blymphoma (Kwak et al, 1992; Wen and Lim, 1997) and multiple myeloma (Wen et al, 1998a (Wen et al, , 1998b Lim and Bailey-Wood, 1999) , efforts have been concentrated primarily on the targeting of the idiotypic proteins or peptides. In leukaemias, various fusion genes arising due to specific chromosomal translocation have been the targets (Pawelec et al, 1996) . Whole cell immunization strategies (Choudhury et al, 1997; Coleman et al, 1997; Lim et al, 1998) further supported the presence of immunogenic peptides, which could be recognized by host T-cells. A recent study (Sahin et al, 1995) suggested that tumour cells often elicit multiple specific immune responses in the autologous host. Whilst some tumour antigens associated with haematological malignancies are well known, others remain to be determined.
A new class of tumour antigens, known as CT (cancer/testis) antigens, has recently been described (Old and Chen, 1998) . They include members of the MAGE family, BAGE and GAGE. They are normal testicular antigens expressed aberrantly in tumour cells. The restricted normal expression of these antigens makes them ideal molecules for immune targeting. Most of these antigens have been isolated through serological screening of expression recombinant libraries constructed from tumour RNA. Whilst the expression of these antigens in normal tissues and in solid tumour cells are established , evidence relating to the pattern of expression in haematological malignancies is scarce. Expression of MAGE-1, MAGE-3, BAGE and GAGE-1,2 have been investigated in leukaemias (reviewed by van den Eynde and van der Bruggen, 1997) but their expression was not demonstrated except in T-cell leukaemias related to HTLV-1 infection. In this study, we have examined the expression of a panel of three known CT antigens, SSX2, NY-ESO-1 and SCP1, in tumour cells derived from a cohort of patients with haematological malignancies and leukaemia cell lines, CEM, HL60 and Molt 4.
MATERIALS AND METHODS
A total of three leukaemia cell lines (CEM, HL60 and Molt 4), six normal bone marrow and 107 tumour specimens (30 chronic myeloid leukaemia (CML), 52 acute myeloid leukaemia (AML), 20 multiple myeloma (MM) and five acute lymphoblastic leukaemia (ALL) were analysed. All samples were collected at disease presentation without any prior therapy. All 30 CML were in chronic phase of the disease. The French-American-British (FAB) subtypes of the 52 AML were: ten M 1 , 26 M 2 , four M 3 , nine M 4 and three M 5 .
Total RNA was isolated from tumour cells using standard RNAzol method. The mRNA expression of these CT antigens was evaluated using reverse transcription (RT) and polymerase chain reaction (PCR). RT was carried out in each sample using random hexamer primers on 1 µg of total RNA. The PCR primers for each of the CT antigen are: NY-ESO-1: ESO-1A, 5′-CAC ACA GGA TCC ATG GAT GCT GCA GAT GCG G-3′ and ESO-1B, 5′-CAC ACA AAG CTT GGC TTA GCG CCT CTG CCC TG-3′ ; SSX2: SSX2A, 5′-GTG CTC AAA TAC CAG AGA AGA TC-3′ and SSX2B, 5′-TTT TGG GTC CAG ATC TCT CGT G-3′ ; SCP1: SCP1A, 5′-CTA CTG TCT GCA GCT TGG-3′ and SCP1B, 5′-CTC GTT TCG AGC TCA GTT-3′. These primer pairs amplify cDNA segments of 300-400 bp in lengths. PCR was performed using 35 amplification cycles in a thermal cycler at annealing temperature of 60°C for NY-ESO-1, 65°C for SSX2 and 55°C for SCP1. Each set of PCR reactions contained a positive control of cDNA derived from normal testis and a negative control of all the PCR reaction mixture except for cDNA which was substituted with water. The integrity of RNA was checked in each PCR reaction by multiplex amplification for the c-abl gene segment. All positive amplifications, as visualized on ethidium bromide agarose gels, were confirmed by two independent RT-PCR and the specificity of the PCR products by Southern blot analysis using the respective probes derived from the PCR amplification products of testicular cDNA. Table 1 shows the mRNA expression of these CT antigens in tumour cells derived from haematological malignancies. All three antigens were not detected in normal bone marrow. SCP1 mRNA was detected in 2/20 (10%) myeloma, 3/52 (5.7%) AML and 7/30 (23%) CML samples. Of the three AML giving a PCR product, SCP1 was detected in two M 2 and one M 4 . It was, however, not detected in all three leukaemia cell lines. In all cases, amplification of c-abl was successful. Although the PCR was not designed primarily to give accurate mRNA quantitation, the reproducibly much less intense radiography signals obtained from Southern blot analysis when compared to those obtained with normal testicular PCR products would suggest low levels of SCP1 expression in tumour cells derived from haematological malignancies ( Figure  1) . In contrast to SCP1, SSX2 and NY-ESO-1 were not detected in any of the 107 tumour specimens and three leukaemia cell lines evaluated.
RESULTS

DISCUSSION
Recent advances in tumour immunology and immunotherapy have been in part due to the successful identification of tumour antigens. In this study, we set out to determine the gene expression of three known CT antigens in haematological malignancies because information relating to these antigens had been derived primarily from solid tumours. Detection of these antigens in haematological malignancies may permit their use for immune targeting in these malignancies.
Using the techniques of RT-PCR followed by Southern blot analysis, we did not detect any transcripts for NY-ESO-1 and SSX-2 in any of the tumour samples. Taken together with a previous study showing the lack of expression of NY-ESO-1 in ten lymphoma samples and SSX2 in 14 leukaemia/lymphoma (Tureci et al, 1998a) , it is likely that these transcripts are rarely expressed in haematological malignancies. In contrast to NY-ESO-1 and SSX-2 and a previous study including 14 leukaemia/lymphoma in which the SCP1 transcript could not be detected (Tureci et al, 1998b) , we have found that the expression of SCP1 in the tumour cells from some haematological malignancies. SCP1 is involved in the pairing of chromosomes during meiosis. It is at present the only CT antigen with a known function. It has been identified as a member of the CT antigen following serological screening of a recombinant cDNA library derived from tumour cells, indicating its ability to elicit immune responses in the cancer host. Its expression in haematological malignancies has never been previously reported. Although its mRNA expression is probably much lower than that in normal testis, its prevalence, especially amongst patients with CML may suggest a potential role for its use for immune targeting of the leukaemia. This obviously would require the appropriate processing and presentation of the peptide in association with the host MHC molecules. Its low level of expression may not be a problem if primary immune responses could first be triggered with synthetic peptides since target recognition by T-cells requires only very low copy number of peptides on the cell surface. Further work is ongoing to determine the in vivo immunogenicity of the SCP1 antigens in patients with tumour cells expressing the SCP1 mRNA. P]-ATP end-labelled probe derived from SCP1 amplification of normal testicular cDNA. Washing was performed under high stringency conditions, with the final wash of the filter at 0.2 × standard saline citrate and 0.1% sodium dodecyl sulphate at 60°C for 20 min. DNA was visualized by autoradiography after overnight exposure. Lanes 1 and 6 showed positive signals of the expected size from the PCR amplification of tumour cell cDNA from two CML patients (lanes 2, 3, 4 and 8 = AML; lane 5 = ALL; lanes 7 and 9 = MM; lane 10 = CML). In contrast, the signal in lane 11, derived from amplification of normal testicular cDNA, was much stronger. Lane 12 consisted of a negative control amplification
